MRNS - INVESTOR ALERT: Edelson Lechtzin LLP Urges Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) Shareholders to Consult Counsel About the Pending Securities Fraud Class Action | Benzinga
NEWTOWN, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) between May 17, 2021, and May 7, 2024, inclusive (the "Class Period").
Investors who purchased Marinus Pharmaceuticals stock may move the U.S. District Court for the Eastern District of Pennsylvania to appoint them as lead plaintiff, no later than August 5, 2024. Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at elechtzin@edelson-law.com. A copy of the class action complaint can be viewed HERE.
What is the Role of a Lead Plaintiff?
The lead plaintiff is a court-appointed representative of a class of purchasers of securities in a class action under the federal securities fraud laws. The lead plaintiff selects the attorneys who will represent the class in the lawsuit. Among other things, the lead plaintiff reviews the complaint, stays informed about the progress of the case, and if necessary, provides testimony at trial.
Background on Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, headquartered in Radnor, Pennsylvania, makes and sells treatments for people with rare genetic epilepsies ...
MRNS) Shareholders to Consult Counsel About the Pending Securities Fraud Class Action>Full story available on Benzinga.com